Acrivon Therapeutics, Inc. Common Stock

NASDAQ: ACRV · Healthcare · Biotechnology

PublicHQ Watertown, MA · MiddlesexCIK 0001781174Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 46DQ —GM —SS 44

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$77.9M

Employees

as of 2026-08-19

Market cap

$87.7M

as of 2026-08-19

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$77.9M-$77.9M2025

Operating income-$84.1M-$84.1M2025

Total assets$129.7M$129.7M2025

Liabilities$17.2M$17.2M2025

Equity$112.5M$112.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Acrivon Therapeutics, Inc. Common Stock’s financial profile?

Acrivon Therapeutics, Inc. Common Stock earned -$77.9M in FY2025 net income.

Peers · Healthcare

Park Dental Partners, Inc. Common Stock——Hemab Therapeutics Holdings, Inc. Common Stock——Cognition Therapeutics, Inc.——NDT Pharmaceuticals Inc.——Aldeyra The——Oncolytics Biotech Inc.——

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Symbotic Inc.$2.2B49D

Key facts

CEOPeter Blume-Jensen

SectorHealthcare

IndustryBiotechnology

HeadquartersWatertown, MA

ExchangeNASDAQ: ACRV

Employees75

IPO date2022-11-15

Latest filings

8-K2026-08-12 10-Q2026-08-12 8-K2026-06-17 8-K2026-05-13 10-Q2026-05-13 DEF 14A2026-04-30 10-K2026-03-19 8-K2026-03-19

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.